ÂÜÀòÂÒÂ×

Susan has over 20 years of combined industry and academic experience, successfully leading programs through IND clearance to full regulatory approval. Susan has led development, registration, and post-marketing support of products for bile duct, urothelial, gastric, breast, prostate, and thyroid cancer and pediatric low-grade glioma. Before joining RayzeBio, she was Chief Medical Officer at QED Therapeutics, an affiliate of BridgeBio Pharma, where she oversaw the clinical development of infigratinib for oncology and skeletal dysplasia indications, leading to the approval of Truseltiq. Prior to QED, Susan was VP and Head of Clinical Development for Puma Biotechnology, contributing to the approval of Nerlynx. Before Puma, she held senior positions at Millennium and Genzyme. Susan also serves on the board of directors of BioAtla.

Susan is a board-certified internist and previously held faculty appointments at the University of Pennsylvania School of Medicine and Harvard Medical School. Susan received her BA from the University of Virginia, MD from Duke University, and MS in Clinical Epidemiology from the University of Pennsylvania School of Medicine.